Genmab A/S expected to post earnings of DKK25.52 a share - Earnings Preview

Genmab A/S

10/02/2025 16:03

* Genmab A/S  GMAB.CO   is expected to show a rise in
quarterly
revenue when it reports  results on February 12 for the period
ending December 31 2024
    * The Valby Denmark-based   company is expected to report a
37.0% increase in revenue to DKK6.409 billion from DKK4.68
billion a year ago, according to the mean estimate from 13
analysts, based on LSEG data. (Majority Sales represents Total
Revenue)
    * ​LSEG's mean analyst estimate for Genmab A/S is for
earnings of
DKK25.52 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 14 "strong buy" or "buy," 9
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Genmab A/S
is
DKK2,350.00​, above​ its last closing price of DKK1,385.00. ​​​

Previous quarterly performance (using preferred earnings measure
in Danish crowns). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  21.88       21.89      19.81     Missed  -9.5
 Jun. 30 2024  20.42       20.56      21.70     Beat    5.5
 Mar. 31 2024  11.54       11.83      20.18     Beat    70.6​
 Dec. 31 2023  23.01       22.95      9.67      Missed  -57.9
 ​​Sep.        20.34       20.49      32.32     Beat    57.8
 30 2023                                                
 Jun. 30 2023  19.60       19.60      20.61     Beat    5.2​
 Mar. 31 2023  5.21        5.34       3.43      Missed  -35.8
 Dec. 31 2022  26.46       26.10      8.77      Missed  -66.4
 This summary was machine generated February 10 at 16:02 GMT. 
All figures in Danish crowns unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)